Novartis and Novo Nordisk's heart drugs fail in trials

• Novartis and Ionis Pharmaceuticals announced their drug failed to meet trial goals.
• Novartis' drug, Pelacarsen, aimed to reduce inherited heart risk but did not prevent heart attacks or strokes.
• Doctors were surprised by the failure of the promising new medicine against heart disease.
• Novartis has decided to abandon further development of the heart drug.
• The unexpected failure of the drug has left experts guessing about the reasons behind it.